nodes	percent_of_prediction	percent_of_DWPC	metapath
Mirabegron—SLCO1A2—Chlorambucil—testicular cancer	0.359	0.424	CbGbCtD
Mirabegron—BCHE—Cisplatin—testicular cancer	0.106	0.124	CbGbCtD
Mirabegron—SLCO1A2—Methotrexate—testicular cancer	0.0643	0.0759	CbGbCtD
Mirabegron—ABCB1—Dactinomycin—testicular cancer	0.0466	0.055	CbGbCtD
Mirabegron—ALB—Methotrexate—testicular cancer	0.0332	0.0392	CbGbCtD
Mirabegron—CYP3A4—Ifosfamide—testicular cancer	0.033	0.0389	CbGbCtD
Mirabegron—ABCB1—Vinblastine—testicular cancer	0.0292	0.0344	CbGbCtD
Mirabegron—CYP2D6—Vinblastine—testicular cancer	0.0275	0.0325	CbGbCtD
Mirabegron—ABCB1—Cisplatin—testicular cancer	0.0268	0.0316	CbGbCtD
Mirabegron—ABCB1—Etoposide—testicular cancer	0.0263	0.031	CbGbCtD
Mirabegron—ABCB1—Doxorubicin—testicular cancer	0.0179	0.0212	CbGbCtD
Mirabegron—CYP3A4—Vinblastine—testicular cancer	0.0175	0.0206	CbGbCtD
Mirabegron—ABCB1—Methotrexate—testicular cancer	0.0174	0.0205	CbGbCtD
Mirabegron—CYP2D6—Doxorubicin—testicular cancer	0.0169	0.0199	CbGbCtD
Mirabegron—CYP3A4—Etoposide—testicular cancer	0.0158	0.0186	CbGbCtD
Mirabegron—CYP3A4—Doxorubicin—testicular cancer	0.0108	0.0127	CbGbCtD
Mirabegron—Gastrointestinal disorder—Chlorambucil—testicular cancer	0.00068	0.00447	CcSEcCtD
Mirabegron—Fatigue—Chlorambucil—testicular cancer	0.000679	0.00447	CcSEcCtD
Mirabegron—Cystitis noninfective—Methotrexate—testicular cancer	0.000675	0.00444	CcSEcCtD
Mirabegron—Cystitis—Methotrexate—testicular cancer	0.000667	0.00439	CcSEcCtD
Mirabegron—Vaginal infection—Methotrexate—testicular cancer	0.000652	0.00429	CcSEcCtD
Mirabegron—Infestation NOS—Etoposide—testicular cancer	0.000645	0.00424	CcSEcCtD
Mirabegron—Infestation—Etoposide—testicular cancer	0.000645	0.00424	CcSEcCtD
Mirabegron—Gastrointestinal pain—Chlorambucil—testicular cancer	0.000644	0.00424	CcSEcCtD
Mirabegron—Stevens-Johnson syndrome—Etoposide—testicular cancer	0.00064	0.00421	CcSEcCtD
Mirabegron—Cystitis noninfective—Epirubicin—testicular cancer	0.000632	0.00415	CcSEcCtD
Mirabegron—Urticaria—Chlorambucil—testicular cancer	0.000626	0.00412	CcSEcCtD
Mirabegron—Neoplasm—Methotrexate—testicular cancer	0.000625	0.00411	CcSEcCtD
Mirabegron—Bladder pain—Methotrexate—testicular cancer	0.000625	0.00411	CcSEcCtD
Mirabegron—Urinary tract disorder—Cisplatin—testicular cancer	0.000625	0.00411	CcSEcCtD
Mirabegron—Cystitis—Epirubicin—testicular cancer	0.000625	0.00411	CcSEcCtD
Mirabegron—Abdominal pain—Chlorambucil—testicular cancer	0.000623	0.00409	CcSEcCtD
Mirabegron—Connective tissue disorder—Cisplatin—testicular cancer	0.000621	0.00409	CcSEcCtD
Mirabegron—Urethral disorder—Cisplatin—testicular cancer	0.00062	0.00408	CcSEcCtD
Mirabegron—Constipation—Vinblastine—testicular cancer	0.000617	0.00406	CcSEcCtD
Mirabegron—Vaginal infection—Epirubicin—testicular cancer	0.000611	0.00401	CcSEcCtD
Mirabegron—Infection—Bleomycin—testicular cancer	0.000606	0.00398	CcSEcCtD
Mirabegron—Vision blurred—Ifosfamide—testicular cancer	0.000602	0.00396	CcSEcCtD
Mirabegron—Dry eye—Epirubicin—testicular cancer	0.000597	0.00393	CcSEcCtD
Mirabegron—Eye disorder—Cisplatin—testicular cancer	0.000591	0.00389	CcSEcCtD
Mirabegron—Gastrointestinal pain—Vinblastine—testicular cancer	0.00059	0.00388	CcSEcCtD
Mirabegron—Cardiac disorder—Cisplatin—testicular cancer	0.000587	0.00386	CcSEcCtD
Mirabegron—Neoplasm—Epirubicin—testicular cancer	0.000585	0.00384	CcSEcCtD
Mirabegron—Bladder pain—Epirubicin—testicular cancer	0.000585	0.00384	CcSEcCtD
Mirabegron—Cystitis noninfective—Doxorubicin—testicular cancer	0.000585	0.00384	CcSEcCtD
Mirabegron—Cystitis—Doxorubicin—testicular cancer	0.000578	0.0038	CcSEcCtD
Mirabegron—Urinary tract disorder—Etoposide—testicular cancer	0.000572	0.00376	CcSEcCtD
Mirabegron—Abdominal pain—Vinblastine—testicular cancer	0.000571	0.00375	CcSEcCtD
Mirabegron—Urethral disorder—Etoposide—testicular cancer	0.000568	0.00373	CcSEcCtD
Mirabegron—Asthenia—Chlorambucil—testicular cancer	0.000565	0.00372	CcSEcCtD
Mirabegron—Infection—Dactinomycin—testicular cancer	0.000565	0.00371	CcSEcCtD
Mirabegron—Vaginal infection—Doxorubicin—testicular cancer	0.000565	0.00371	CcSEcCtD
Mirabegron—Palpitations—Ifosfamide—testicular cancer	0.000564	0.00371	CcSEcCtD
Mirabegron—Pruritus—Chlorambucil—testicular cancer	0.000557	0.00366	CcSEcCtD
Mirabegron—Musculoskeletal discomfort—Bleomycin—testicular cancer	0.000556	0.00365	CcSEcCtD
Mirabegron—Dry eye—Doxorubicin—testicular cancer	0.000553	0.00363	CcSEcCtD
Mirabegron—Hypertension—Ifosfamide—testicular cancer	0.000551	0.00362	CcSEcCtD
Mirabegron—Erythema multiforme—Etoposide—testicular cancer	0.000548	0.0036	CcSEcCtD
Mirabegron—Arthralgia—Ifosfamide—testicular cancer	0.000544	0.00357	CcSEcCtD
Mirabegron—Eye disorder—Etoposide—testicular cancer	0.000541	0.00356	CcSEcCtD
Mirabegron—Neoplasm—Doxorubicin—testicular cancer	0.000541	0.00356	CcSEcCtD
Mirabegron—Bladder pain—Doxorubicin—testicular cancer	0.000541	0.00356	CcSEcCtD
Mirabegron—Unspecified disorder of skin and subcutaneous tissue—Ifosfamide—testicular cancer	0.00054	0.00355	CcSEcCtD
Mirabegron—Diarrhoea—Chlorambucil—testicular cancer	0.000539	0.00354	CcSEcCtD
Mirabegron—Cardiac disorder—Etoposide—testicular cancer	0.000538	0.00354	CcSEcCtD
Mirabegron—Vascular purpura—Epirubicin—testicular cancer	0.000525	0.00345	CcSEcCtD
Mirabegron—Vision blurred—Cisplatin—testicular cancer	0.000519	0.00341	CcSEcCtD
Mirabegron—Musculoskeletal discomfort—Dactinomycin—testicular cancer	0.000518	0.00341	CcSEcCtD
Mirabegron—Asthenia—Vinblastine—testicular cancer	0.000518	0.00341	CcSEcCtD
Mirabegron—Infection—Ifosfamide—testicular cancer	0.000518	0.0034	CcSEcCtD
Mirabegron—Cerebrovascular accident—Methotrexate—testicular cancer	0.000512	0.00337	CcSEcCtD
Mirabegron—Skin disorder—Ifosfamide—testicular cancer	0.000506	0.00333	CcSEcCtD
Mirabegron—Osteoarthritis—Methotrexate—testicular cancer	0.000502	0.0033	CcSEcCtD
Mirabegron—Diarrhoea—Vinblastine—testicular cancer	0.000494	0.00325	CcSEcCtD
Mirabegron—Fatigue—Dactinomycin—testicular cancer	0.00049	0.00322	CcSEcCtD
Mirabegron—Back pain—Etoposide—testicular cancer	0.000488	0.00321	CcSEcCtD
Mirabegron—Purpura—Epirubicin—testicular cancer	0.000487	0.0032	CcSEcCtD
Mirabegron—Vascular purpura—Doxorubicin—testicular cancer	0.000486	0.00319	CcSEcCtD
Mirabegron—Urticaria—Bleomycin—testicular cancer	0.000484	0.00318	CcSEcCtD
Mirabegron—Cerebrovascular accident—Epirubicin—testicular cancer	0.000479	0.00315	CcSEcCtD
Mirabegron—Dizziness—Vinblastine—testicular cancer	0.000477	0.00314	CcSEcCtD
Mirabegron—Musculoskeletal discomfort—Ifosfamide—testicular cancer	0.000475	0.00312	CcSEcCtD
Mirabegron—Osteoarthritis—Epirubicin—testicular cancer	0.000469	0.00309	CcSEcCtD
Mirabegron—Nausea—Chlorambucil—testicular cancer	0.000468	0.00308	CcSEcCtD
Mirabegron—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—testicular cancer	0.000465	0.00306	CcSEcCtD
Mirabegron—Gastrointestinal pain—Dactinomycin—testicular cancer	0.000465	0.00306	CcSEcCtD
Mirabegron—Breast disorder—Methotrexate—testicular cancer	0.000453	0.00298	CcSEcCtD
Mirabegron—Headache—Vinblastine—testicular cancer	0.000452	0.00297	CcSEcCtD
Mirabegron—Purpura—Doxorubicin—testicular cancer	0.000451	0.00296	CcSEcCtD
Mirabegron—Gastrointestinal disorder—Ifosfamide—testicular cancer	0.00045	0.00296	CcSEcCtD
Mirabegron—Abdominal pain—Dactinomycin—testicular cancer	0.00045	0.00296	CcSEcCtD
Mirabegron—Fatigue—Ifosfamide—testicular cancer	0.000449	0.00295	CcSEcCtD
Mirabegron—Infection—Cisplatin—testicular cancer	0.000446	0.00293	CcSEcCtD
Mirabegron—Constipation—Ifosfamide—testicular cancer	0.000446	0.00293	CcSEcCtD
Mirabegron—Cerebrovascular accident—Doxorubicin—testicular cancer	0.000443	0.00291	CcSEcCtD
Mirabegron—Tachycardia—Cisplatin—testicular cancer	0.000439	0.00288	CcSEcCtD
Mirabegron—Asthenia—Bleomycin—testicular cancer	0.000438	0.00288	CcSEcCtD
Mirabegron—Skin disorder—Cisplatin—testicular cancer	0.000436	0.00287	CcSEcCtD
Mirabegron—Hypertension—Etoposide—testicular cancer	0.000435	0.00286	CcSEcCtD
Mirabegron—Osteoarthritis—Doxorubicin—testicular cancer	0.000434	0.00286	CcSEcCtD
Mirabegron—Pruritus—Bleomycin—testicular cancer	0.000431	0.00284	CcSEcCtD
Mirabegron—Nausea—Vinblastine—testicular cancer	0.000429	0.00282	CcSEcCtD
Mirabegron—Unspecified disorder of skin and subcutaneous tissue—Etoposide—testicular cancer	0.000426	0.0028	CcSEcCtD
Mirabegron—Gastrointestinal pain—Ifosfamide—testicular cancer	0.000426	0.0028	CcSEcCtD
Mirabegron—Breast disorder—Epirubicin—testicular cancer	0.000424	0.00279	CcSEcCtD
Mirabegron—Aspartate aminotransferase increased—Epirubicin—testicular cancer	0.000423	0.00278	CcSEcCtD
Mirabegron—Nasopharyngitis—Epirubicin—testicular cancer	0.00042	0.00276	CcSEcCtD
Mirabegron—Gastritis—Epirubicin—testicular cancer	0.000415	0.00273	CcSEcCtD
Mirabegron—Alanine aminotransferase increased—Epirubicin—testicular cancer	0.000414	0.00272	CcSEcCtD
Mirabegron—Urticaria—Ifosfamide—testicular cancer	0.000414	0.00272	CcSEcCtD
Mirabegron—Abdominal pain—Ifosfamide—testicular cancer	0.000412	0.00271	CcSEcCtD
Mirabegron—Musculoskeletal discomfort—Cisplatin—testicular cancer	0.000409	0.00269	CcSEcCtD
Mirabegron—Infection—Etoposide—testicular cancer	0.000409	0.00269	CcSEcCtD
Mirabegron—Abdominal distension—Epirubicin—testicular cancer	0.000408	0.00269	CcSEcCtD
Mirabegron—Asthenia—Dactinomycin—testicular cancer	0.000408	0.00268	CcSEcCtD
Mirabegron—Influenza—Epirubicin—testicular cancer	0.000406	0.00267	CcSEcCtD
Mirabegron—Upper respiratory tract infection—Methotrexate—testicular cancer	0.000403	0.00265	CcSEcCtD
Mirabegron—Tachycardia—Etoposide—testicular cancer	0.000402	0.00264	CcSEcCtD
Mirabegron—Skin disorder—Etoposide—testicular cancer	0.0004	0.00263	CcSEcCtD
Mirabegron—Breast disorder—Doxorubicin—testicular cancer	0.000393	0.00258	CcSEcCtD
Mirabegron—Aspartate aminotransferase increased—Doxorubicin—testicular cancer	0.000391	0.00257	CcSEcCtD
Mirabegron—Diarrhoea—Dactinomycin—testicular cancer	0.000389	0.00256	CcSEcCtD
Mirabegron—Nasopharyngitis—Doxorubicin—testicular cancer	0.000388	0.00255	CcSEcCtD
Mirabegron—Gastrointestinal disorder—Cisplatin—testicular cancer	0.000388	0.00255	CcSEcCtD
Mirabegron—Infestation NOS—Methotrexate—testicular cancer	0.000387	0.00254	CcSEcCtD
Mirabegron—Infestation—Methotrexate—testicular cancer	0.000387	0.00254	CcSEcCtD
Mirabegron—Rash—Bleomycin—testicular cancer	0.000385	0.00253	CcSEcCtD
Mirabegron—Gastritis—Doxorubicin—testicular cancer	0.000384	0.00253	CcSEcCtD
Mirabegron—Dermatitis—Bleomycin—testicular cancer	0.000384	0.00253	CcSEcCtD
Mirabegron—Stevens-Johnson syndrome—Methotrexate—testicular cancer	0.000383	0.00252	CcSEcCtD
Mirabegron—Alanine aminotransferase increased—Doxorubicin—testicular cancer	0.000383	0.00252	CcSEcCtD
Mirabegron—Abdominal distension—Doxorubicin—testicular cancer	0.000378	0.00248	CcSEcCtD
Mirabegron—Upper respiratory tract infection—Epirubicin—testicular cancer	0.000377	0.00248	CcSEcCtD
Mirabegron—Influenza—Doxorubicin—testicular cancer	0.000375	0.00247	CcSEcCtD
Mirabegron—Asthenia—Ifosfamide—testicular cancer	0.000374	0.00246	CcSEcCtD
Mirabegron—Pruritus—Ifosfamide—testicular cancer	0.000369	0.00242	CcSEcCtD
Mirabegron—Nausea—Bleomycin—testicular cancer	0.000362	0.00238	CcSEcCtD
Mirabegron—Infestation NOS—Epirubicin—testicular cancer	0.000362	0.00238	CcSEcCtD
Mirabegron—Infestation—Epirubicin—testicular cancer	0.000362	0.00238	CcSEcCtD
Mirabegron—Stevens-Johnson syndrome—Epirubicin—testicular cancer	0.000359	0.00236	CcSEcCtD
Mirabegron—Rash—Dactinomycin—testicular cancer	0.000359	0.00236	CcSEcCtD
Mirabegron—Diarrhoea—Ifosfamide—testicular cancer	0.000357	0.00234	CcSEcCtD
Mirabegron—Gastrointestinal disorder—Etoposide—testicular cancer	0.000355	0.00234	CcSEcCtD
Mirabegron—Fatigue—Etoposide—testicular cancer	0.000355	0.00233	CcSEcCtD
Mirabegron—Constipation—Etoposide—testicular cancer	0.000352	0.00231	CcSEcCtD
Mirabegron—Urinary tract infection—Epirubicin—testicular cancer	0.000352	0.00231	CcSEcCtD
Mirabegron—Upper respiratory tract infection—Doxorubicin—testicular cancer	0.000349	0.00229	CcSEcCtD
Mirabegron—Dizziness—Ifosfamide—testicular cancer	0.000345	0.00227	CcSEcCtD
Mirabegron—Urinary tract disorder—Methotrexate—testicular cancer	0.000343	0.00225	CcSEcCtD
Mirabegron—Urethral disorder—Methotrexate—testicular cancer	0.00034	0.00224	CcSEcCtD
Mirabegron—Sinusitis—Epirubicin—testicular cancer	0.000339	0.00223	CcSEcCtD
Mirabegron—Nausea—Dactinomycin—testicular cancer	0.000338	0.00222	CcSEcCtD
Mirabegron—Gastrointestinal pain—Etoposide—testicular cancer	0.000337	0.00221	CcSEcCtD
Mirabegron—Infestation NOS—Doxorubicin—testicular cancer	0.000335	0.0022	CcSEcCtD
Mirabegron—Infestation—Doxorubicin—testicular cancer	0.000335	0.0022	CcSEcCtD
Mirabegron—Stevens-Johnson syndrome—Doxorubicin—testicular cancer	0.000332	0.00218	CcSEcCtD
Mirabegron—Rash—Ifosfamide—testicular cancer	0.000329	0.00216	CcSEcCtD
Mirabegron—Dermatitis—Ifosfamide—testicular cancer	0.000328	0.00216	CcSEcCtD
Mirabegron—Erythema multiforme—Methotrexate—testicular cancer	0.000328	0.00216	CcSEcCtD
Mirabegron—Urticaria—Etoposide—testicular cancer	0.000327	0.00215	CcSEcCtD
Mirabegron—Rhinitis—Epirubicin—testicular cancer	0.000326	0.00214	CcSEcCtD
Mirabegron—Abdominal pain—Etoposide—testicular cancer	0.000325	0.00214	CcSEcCtD
Mirabegron—Urinary tract infection—Doxorubicin—testicular cancer	0.000325	0.00214	CcSEcCtD
Mirabegron—Eye disorder—Methotrexate—testicular cancer	0.000324	0.00213	CcSEcCtD
Mirabegron—Asthenia—Cisplatin—testicular cancer	0.000322	0.00212	CcSEcCtD
Mirabegron—Cardiac disorder—Methotrexate—testicular cancer	0.000322	0.00212	CcSEcCtD
Mirabegron—Urinary tract disorder—Epirubicin—testicular cancer	0.000321	0.00211	CcSEcCtD
Mirabegron—Connective tissue disorder—Epirubicin—testicular cancer	0.000319	0.0021	CcSEcCtD
Mirabegron—Urethral disorder—Epirubicin—testicular cancer	0.000318	0.00209	CcSEcCtD
Mirabegron—Sinusitis—Doxorubicin—testicular cancer	0.000314	0.00206	CcSEcCtD
Mirabegron—Nausea—Ifosfamide—testicular cancer	0.00031	0.00204	CcSEcCtD
Mirabegron—Diarrhoea—Cisplatin—testicular cancer	0.000307	0.00202	CcSEcCtD
Mirabegron—Erythema multiforme—Epirubicin—testicular cancer	0.000307	0.00202	CcSEcCtD
Mirabegron—Eye disorder—Epirubicin—testicular cancer	0.000304	0.002	CcSEcCtD
Mirabegron—Cardiac disorder—Epirubicin—testicular cancer	0.000301	0.00198	CcSEcCtD
Mirabegron—Rhinitis—Doxorubicin—testicular cancer	0.000301	0.00198	CcSEcCtD
Mirabegron—Urinary tract disorder—Doxorubicin—testicular cancer	0.000297	0.00195	CcSEcCtD
Mirabegron—Asthenia—Etoposide—testicular cancer	0.000295	0.00194	CcSEcCtD
Mirabegron—Connective tissue disorder—Doxorubicin—testicular cancer	0.000295	0.00194	CcSEcCtD
Mirabegron—Urethral disorder—Doxorubicin—testicular cancer	0.000295	0.00194	CcSEcCtD
Mirabegron—Back pain—Methotrexate—testicular cancer	0.000292	0.00192	CcSEcCtD
Mirabegron—Pruritus—Etoposide—testicular cancer	0.000291	0.00191	CcSEcCtD
Mirabegron—Vision blurred—Methotrexate—testicular cancer	0.000285	0.00187	CcSEcCtD
Mirabegron—Erythema multiforme—Doxorubicin—testicular cancer	0.000284	0.00187	CcSEcCtD
Mirabegron—Rash—Cisplatin—testicular cancer	0.000283	0.00186	CcSEcCtD
Mirabegron—Dermatitis—Cisplatin—testicular cancer	0.000283	0.00186	CcSEcCtD
Mirabegron—Diarrhoea—Etoposide—testicular cancer	0.000282	0.00185	CcSEcCtD
Mirabegron—Eye disorder—Doxorubicin—testicular cancer	0.000281	0.00185	CcSEcCtD
Mirabegron—Cardiac disorder—Doxorubicin—testicular cancer	0.000279	0.00183	CcSEcCtD
Mirabegron—Back pain—Epirubicin—testicular cancer	0.000273	0.0018	CcSEcCtD
Mirabegron—Dizziness—Etoposide—testicular cancer	0.000272	0.00179	CcSEcCtD
Mirabegron—Nausea—Cisplatin—testicular cancer	0.000267	0.00175	CcSEcCtD
Mirabegron—Vision blurred—Epirubicin—testicular cancer	0.000266	0.00175	CcSEcCtD
Mirabegron—Rash—Etoposide—testicular cancer	0.00026	0.00171	CcSEcCtD
Mirabegron—Dermatitis—Etoposide—testicular cancer	0.000259	0.0017	CcSEcCtD
Mirabegron—Headache—Etoposide—testicular cancer	0.000258	0.0017	CcSEcCtD
Mirabegron—Arthralgia—Methotrexate—testicular cancer	0.000257	0.00169	CcSEcCtD
Mirabegron—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	0.000255	0.00168	CcSEcCtD
Mirabegron—Back pain—Doxorubicin—testicular cancer	0.000253	0.00166	CcSEcCtD
Mirabegron—Palpitations—Epirubicin—testicular cancer	0.00025	0.00164	CcSEcCtD
Mirabegron—Vision blurred—Doxorubicin—testicular cancer	0.000247	0.00162	CcSEcCtD
Mirabegron—Infection—Methotrexate—testicular cancer	0.000245	0.00161	CcSEcCtD
Mirabegron—Nausea—Etoposide—testicular cancer	0.000245	0.00161	CcSEcCtD
Mirabegron—Hypertension—Epirubicin—testicular cancer	0.000244	0.0016	CcSEcCtD
Mirabegron—Arthralgia—Epirubicin—testicular cancer	0.000241	0.00158	CcSEcCtD
Mirabegron—Skin disorder—Methotrexate—testicular cancer	0.000239	0.00157	CcSEcCtD
Mirabegron—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	0.000239	0.00157	CcSEcCtD
Mirabegron—Dry mouth—Epirubicin—testicular cancer	0.000235	0.00155	CcSEcCtD
Mirabegron—Palpitations—Doxorubicin—testicular cancer	0.000231	0.00152	CcSEcCtD
Mirabegron—Infection—Epirubicin—testicular cancer	0.000229	0.00151	CcSEcCtD
Mirabegron—Hypertension—Doxorubicin—testicular cancer	0.000226	0.00148	CcSEcCtD
Mirabegron—Tachycardia—Epirubicin—testicular cancer	0.000225	0.00148	CcSEcCtD
Mirabegron—Musculoskeletal discomfort—Methotrexate—testicular cancer	0.000225	0.00148	CcSEcCtD
Mirabegron—Skin disorder—Epirubicin—testicular cancer	0.000224	0.00147	CcSEcCtD
Mirabegron—Arthralgia—Doxorubicin—testicular cancer	0.000223	0.00146	CcSEcCtD
Mirabegron—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	0.000221	0.00145	CcSEcCtD
Mirabegron—Dry mouth—Doxorubicin—testicular cancer	0.000218	0.00143	CcSEcCtD
Mirabegron—Dyspepsia—Methotrexate—testicular cancer	0.000217	0.00143	CcSEcCtD
Mirabegron—Gastrointestinal disorder—Methotrexate—testicular cancer	0.000213	0.0014	CcSEcCtD
Mirabegron—Fatigue—Methotrexate—testicular cancer	0.000213	0.0014	CcSEcCtD
Mirabegron—Infection—Doxorubicin—testicular cancer	0.000212	0.00139	CcSEcCtD
Mirabegron—Musculoskeletal discomfort—Epirubicin—testicular cancer	0.00021	0.00138	CcSEcCtD
Mirabegron—Tachycardia—Doxorubicin—testicular cancer	0.000208	0.00137	CcSEcCtD
Mirabegron—Skin disorder—Doxorubicin—testicular cancer	0.000207	0.00136	CcSEcCtD
Mirabegron—Dyspepsia—Epirubicin—testicular cancer	0.000203	0.00134	CcSEcCtD
Mirabegron—Gastrointestinal pain—Methotrexate—testicular cancer	0.000202	0.00133	CcSEcCtD
Mirabegron—Gastrointestinal disorder—Epirubicin—testicular cancer	0.000199	0.00131	CcSEcCtD
Mirabegron—Fatigue—Epirubicin—testicular cancer	0.000199	0.00131	CcSEcCtD
Mirabegron—Constipation—Epirubicin—testicular cancer	0.000197	0.0013	CcSEcCtD
Mirabegron—Urticaria—Methotrexate—testicular cancer	0.000196	0.00129	CcSEcCtD
Mirabegron—Abdominal pain—Methotrexate—testicular cancer	0.000195	0.00128	CcSEcCtD
Mirabegron—Musculoskeletal discomfort—Doxorubicin—testicular cancer	0.000195	0.00128	CcSEcCtD
Mirabegron—Gastrointestinal pain—Epirubicin—testicular cancer	0.000189	0.00124	CcSEcCtD
Mirabegron—Dyspepsia—Doxorubicin—testicular cancer	0.000188	0.00124	CcSEcCtD
Mirabegron—Gastrointestinal disorder—Doxorubicin—testicular cancer	0.000184	0.00121	CcSEcCtD
Mirabegron—Fatigue—Doxorubicin—testicular cancer	0.000184	0.00121	CcSEcCtD
Mirabegron—Urticaria—Epirubicin—testicular cancer	0.000183	0.00121	CcSEcCtD
Mirabegron—Constipation—Doxorubicin—testicular cancer	0.000183	0.0012	CcSEcCtD
Mirabegron—Abdominal pain—Epirubicin—testicular cancer	0.000182	0.0012	CcSEcCtD
Mirabegron—Asthenia—Methotrexate—testicular cancer	0.000177	0.00116	CcSEcCtD
Mirabegron—Gastrointestinal pain—Doxorubicin—testicular cancer	0.000175	0.00115	CcSEcCtD
Mirabegron—Pruritus—Methotrexate—testicular cancer	0.000174	0.00115	CcSEcCtD
Mirabegron—Urticaria—Doxorubicin—testicular cancer	0.00017	0.00112	CcSEcCtD
Mirabegron—Abdominal pain—Doxorubicin—testicular cancer	0.000169	0.00111	CcSEcCtD
Mirabegron—Diarrhoea—Methotrexate—testicular cancer	0.000169	0.00111	CcSEcCtD
Mirabegron—Asthenia—Epirubicin—testicular cancer	0.000166	0.00109	CcSEcCtD
Mirabegron—Pruritus—Epirubicin—testicular cancer	0.000163	0.00107	CcSEcCtD
Mirabegron—Dizziness—Methotrexate—testicular cancer	0.000163	0.00107	CcSEcCtD
Mirabegron—Diarrhoea—Epirubicin—testicular cancer	0.000158	0.00104	CcSEcCtD
Mirabegron—Rash—Methotrexate—testicular cancer	0.000155	0.00102	CcSEcCtD
Mirabegron—Dermatitis—Methotrexate—testicular cancer	0.000155	0.00102	CcSEcCtD
Mirabegron—Headache—Methotrexate—testicular cancer	0.000154	0.00102	CcSEcCtD
Mirabegron—Asthenia—Doxorubicin—testicular cancer	0.000153	0.00101	CcSEcCtD
Mirabegron—Dizziness—Epirubicin—testicular cancer	0.000153	0.001	CcSEcCtD
Mirabegron—Pruritus—Doxorubicin—testicular cancer	0.000151	0.000993	CcSEcCtD
Mirabegron—Nausea—Methotrexate—testicular cancer	0.000146	0.000963	CcSEcCtD
Mirabegron—Diarrhoea—Doxorubicin—testicular cancer	0.000146	0.00096	CcSEcCtD
Mirabegron—Rash—Epirubicin—testicular cancer	0.000145	0.000956	CcSEcCtD
Mirabegron—Dermatitis—Epirubicin—testicular cancer	0.000145	0.000956	CcSEcCtD
Mirabegron—Headache—Epirubicin—testicular cancer	0.000145	0.00095	CcSEcCtD
Mirabegron—Dizziness—Doxorubicin—testicular cancer	0.000141	0.000928	CcSEcCtD
Mirabegron—Nausea—Epirubicin—testicular cancer	0.000137	0.000901	CcSEcCtD
Mirabegron—Rash—Doxorubicin—testicular cancer	0.000135	0.000885	CcSEcCtD
Mirabegron—Dermatitis—Doxorubicin—testicular cancer	0.000134	0.000884	CcSEcCtD
Mirabegron—Headache—Doxorubicin—testicular cancer	0.000134	0.000879	CcSEcCtD
Mirabegron—Nausea—Doxorubicin—testicular cancer	0.000127	0.000834	CcSEcCtD
